Evidence for suboptimal use of periconceptional folic acid supplements globally.

OBJECTIVE: To systematically summarise the available evidence concerning the rate of folic acid supplement use pre- and periconceptionally, to identify those characteristics associated with low rates of use and to assess whether folic acid public awareness campaigns are associated with higher folic acid use. DESIGN: Systematic overview. SETTING: Survey studies. POPULATION: Women of reproductive age, most of whom were currently or recently pregnant. METHODS: Two investigators searched MEDLINE, Embase and Nutriotiongate databases between 1990 and 2003. Bibliographies of retrieved references were scanned for other relevant publications, and authors were contacted if necessary. Studies were included that evaluated the rate of folic acid supplement use either before conception or in early pregnancy. MAIN OUTCOME MEASURES: Rate of preconceptional and/or periconceptional folic acid use, rate of planned pregnancy in each study, as well as significant characteristics differentiating non-users from users of folic acid, including the effect of folic acid awareness campaigns. RESULTS: A total of 52 studies were included. In 34 studies, reported preconceptional folic acid use varied from 0.9% to 50%. In 49 studies, the reported rate of periconceptional supplement use ranged from 0.5% to 52%. Significant predictors of reduced periconceptional folic acid use were a low level of formal education, immigrant status, young maternal age, lack of a partner and an unplanned pregnancy. Four studies examined the effect of mass media campaigns on periconceptional folic acid use; the reported rates increased significantly, by a factor of 1.7 to 7.2, but in no study was the post-campaign rate above 50%. CONCLUSIONS: In many countries, fewer than 50% of women take periconceptional folic acid supplements. Consideration should be given to the practical advantages of folic acid fortification of centrally processed foods, such as wheat, corn and rice flour, while further promoting vitamin tablet supplement use and planned pregnancy.

Haematological problems in pregnancy.

PURPOSE OF REVIEW: Haematological disorders of pregnancy are common reasons for referral. It is reasonable then to devote a review to recent publications on these issues. RECENT FINDINGS: Several narrative reviews on the management of venous thromboembolic disease in pregnancy provide exceptional guidance. They highlight, however, that most of what is done is still based on opinions from highly qualified people, extrapolated from the non-pregnant literature but not involving randomized trials on pregnant patients. It is apparent that a consensus is nearing on the management of both pregnancy-related thrombocytopenia and idiopathic (immune) thrombocytopenic purpura. Several randomized controlled trials are reported on the treatment of non-deficiency anaemia, using oral iron, intravenous iron and erythropoietin, which contribute to the debate on the appropriate and best intervention for this common problematic issue. SUMMARY: This review demonstrates the need for appropriately sized randomized trials on haematological issues in pregnancy. With heparin becoming the most common medication being administered prophylactically and therapeutically in pregnancy, it is important that quality trials are performed to guide its sensible utilization.

Prothrombin G20210A mutation is not associated with recurrent miscarriages.

OBJECTIVE: To assess the association between prothrombin G20210A mutation and recurrent miscarriages. STUDY DESIGN: A literature review was performed in Medline identifying articles from 1966 to December 2000. Articles meeting inclusion criteria were systematically reviewed and included in a meta-analysis. RESULTS: Six trials, all case-controlled, were identified. These trials included 323 women with recurrent pregnancy loss. The odds ratio (OR) for heterozygous prothrombin mutation was 1.9 (95% confidence interval (CI) 0.98-4.14), and for homozygous prothrombin mutation was 3.76 (95% CI 0.75-18.77). The OR for prothrombin mutation and primary recurrent abortion was 2.19 (95% CI 0.61-7.89) and for prothrombin mutation and secondary recurrent abortion was 1.29 (95% CI 0.2-8.36). CONCLUSION: There is no evidence to support an association of prothrombin G20210A mutation with recurrent miscarriages.

Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2).

BACKGROUND: Uncertainty remains about the potential harmful effects of antihypertensive therapy on the developing fetus, especially for beta-blockers (betab). METHODS: We prospectively enrolled all singleton women with a blood pressure >/= 140/90 mm Hg during pregnancy. The main analysis included 1948 women with all forms of hypertension and compared the use of betab drugs, non-betab drugs or a combination of both, to no treatment. The primary study outcome was a composite of the diseases of prematurity, need for assisted ventilation for greater than 1 day, or perinatal death. A sub-group analysis evaluated the four treatment options among 583 singleton women with chronic hypertension before 20 weeks gestation. RESULTS: In the main analysis, no association was observed between betab use and the primary composite outcome [adjusted odds ratio (OR) 1.4, 95% CI 0.9-2.2], while an association was seen with non-betab therapy (OR 5.0, 95% CI 2.6-9.6) and combination therapy (OR 2.9, 95% CI 1.8-4.7). In the sub-group of 583 women with hypertension before 20 weeks, use of a non-betab drug (OR 4.9, 95% CI 1.7-14.2) or combination therapy (OR 2.9. 95% CI 1.1-7.7) was significantly associated with the primary composite outcome, while betab monotherapy was not (OR 1.4, 95% CI 0.6-3.4). CONCLUSIONS: Maternal use of antihypertensive medications other than betabs was associated with both major perinatal morbidity and mortality, while betab monotherapy was not. The combined use of betab and non-betab medications demonstrated the strongest association. Before definitive conclusions can be drawn, a large multicentre randomized controlled trial is needed to address the issues of both maternal efficacy and fetal safety with the use of one or more antihypertensive agents in pregnancy.